NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
Clinical Trials
10 trialsNCT02542397 2022-11-03
LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01192815 2020-05-12
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT01547923 2020-03-25
DPD côlon
Institut Cancerologie de l'Ouest
Phase NA Terminated
NCT01907802 2018-08-14
Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01208064 2018-07-12
Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Terminated
NCT01705106 2018-05-30
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
University of Chicago
Phase 1 Terminated
NCT01599832 2017-06-08
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
University of Chicago
Phase NA Terminated
NCT01126502 2015-11-04
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01071564 2015-04-15
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated